Lauren White

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Watertown, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Lana Gladstein, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Lauren White

Form 4 holding Chief Financial Officer

C4 Therapeutics, Inc.

Security class
Common Stock
Shares / value
32,686
Estimated value
$213,113
Report date
30 Aug 2023
Price
$6.52
Ownership
Direct
Form 4 holding Chief Financial Officer

C4 Therapeutics, Inc.

Security class
Performance Restricted Stock Units
Shares / value
16,500
Estimated value
$104,940
Report date
30 Aug 2023
Price
$6.36
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding SVP, CFO AND PFO

ImmunoGen, Inc.

Security class
Restricted Stock Unit
Shares / value
0
Estimated value
$0
Report date
12 Feb 2024
Price
$29.30
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding SVP, CFO AND PFO

ImmunoGen, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
$0
Report date
12 Feb 2024
Price
$4.56
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Seaport Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
63,680
Estimated value
Report date
30 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Seaport Therapeutics, Inc.

Security class
Common Stock
Shares / value
6,702
Estimated value
Report date
04 May 2026
Price
Ownership
By Lauren Anne White Living Trust, dated January 30, 2020
Form 4 holding Chief Financial Officer

Seaport Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
04 May 2026
Price
Ownership
By Lauren Anne White Living Trust, dated January 30, 2020
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Lauren White

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .